INSIGHTS ON PHARMACEUTICAL INSPECTION

• A Comprehensive Guide To Sampling Protocols And Robust CCI Testing

  Effective CCI testing hinges on strategic sampling and statistical rigor. Learn why 30 samples matter, how positive controls validate defect detection, and why risk assessment ensures long-term reliability.

• Effective Strategies To Minimize Product Loss During Fill Finish

  Every drop of high-value biologic lost in fill finish is money left on the table. Learn practical strategies to protect your yield.

• EU And PIC/S Annex 1: CCS Shortfalls After 2 Years Of Implementation

  Explore how to elevate Contamination Control Strategies from static documents to inspection-ready, lifecycle tools, as well as practical approaches to Annex 1 compliance and risk-based CCS development.

• Microbial Ingress No Longer An Effective CCI Test Method

  Microbial ingress testing is no longer a reliable measure of container closure integrity. Learn why its variability and limitations demand a shift to deterministic methods that deliver accurate results.

• Multi‑Sample Testing With Precise Failure Detection For Throughput

  12/29/2025

  Test multiple samples at once with a multi‑sample testing platform that ensures accurate detection for low headspace formats and integrates into automated lines for high-volume efficiency.

• Start Packaging Development Early

  5/12/2026

  To avoid costly delays later in the product lifecycle, it is essential to plan for key variables early and select container closure systems with confidence from the outset.

• Advancing Drug Product Quality Through AVI And Future-Ready Infrastructure

  9/5/2025

  Automated visual inspection (AVI) combines robotics, precision imaging, and sophisticated defect-recognition software to provide a scalable solution for expanding pipelines and rises in production volumes.

• Visual Inspection Equipment To Deliver The Highest Product Integrity

  4/1/2025

  Gain insight into an advanced inspection solution for pharmaceuticals that ensures drug integrity and reduces costs with flexible technologies, from lab development to high-volume production.

• USP Draft Chapters On CCS: What You Need To Know

  5/12/2026

  Learn why it's important to stay aligned with evolving Annex 1 expectations to support sterility assurance, regulatory compliance, and patient safety across sterile drug manufacturing operations.